ESR1 and breast cancer: In summary, PI3K pathway activation was shown to promote acquired resistance to long-term endocrine deprivation in preclinical models of ER+ breast cancer cell lines, and proteomic profiling revealed increased phosphorylation of mTOR and Akt [41,42].